Agios Pharmaceuticals, Inc. AGIO
31.38 USD +1.97 (+6.70%)
At closeNov 9, 2026, 4:54 PM EST
31.98 +0.60 +1.91%
After hours · Nov 9, 4:54 PM ET
28.93 Day range 31.45
22.24 52-week range 46.00
- YTD
- +15.28%
- 1 year
- -22.84%
News
seekingalpha.com Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Cecilia…
benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $37 to $35.
benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62 HC Wainwright & Co. analyst Douglas Tsao maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $55 to $62.
marketbeat.com What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call Agios Pharmaceuticals NASDAQ: AGIO reported record third-quarter product revenue as its thalassemia drug AQVESME continued its U.S. launch, while the company prepares for a delayed regulatory…
zacks.com Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.78 per share a year ago.
benzinga.com Agios Pharmaceuticals Q3 2026 Earnings Call Transcript Agios Pharmaceuticals (NASDAQ:AGIO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Agios Pharmaceuticals Q3 EPS $(1.09) Beats $(1.20) Estimate, Sales $55.385M Beat $53.208M Estimate Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.20) by 9.17 percent. This is a 38.76 percent increase over losses…
globenewswire.com Agios Reports Third Quarter 2026 Financial Results and Provides Business Update Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S.…
globenewswire.com Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026 Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.- benzinga.com Agios Pharmaceuticals Says FDA Extends Mitapivat PDUFA Date For Sickle Cell Disease To February 1, 2027 FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major…
benzinga.com HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55 HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.
benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50 B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.
benzinga.com Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.
benzinga.com JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34 JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.- benzinga.com Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52 Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
- benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.
- benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55 HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $52 to $55.
benzinga.com Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.67) by 1.2 percent. This is a 12.44 percent increase over losses…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Agios Reports Neutral Sickle Cell Data, Decides To Stop Development Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52 HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $54 to $52.
benzinga.com Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.- benzinga.com Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in…
benzinga.com Why Is Agios Pharma Stock Soaring Tuesday? Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.- benzinga.com RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32 RBC Capital analyst Luca Issi maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Perform and raises the price target from $28 to $32.
benzinga.com DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.- benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $36 to $41.
- benzinga.com Agios Pharma Says FDA Accepts sNDA For Mitapivat In Sickle Cell Disease With Priority Review; PDUFA Goal Date November 1 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food…
- benzinga.com B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $46 B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $40 to $46.
- benzinga.com Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response Rate And 41.1% Reduction In Transfusion Burden Versus Placebo In Sickle Cell Disease Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients in mitapivat arm had…
- benzinga.com JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31 JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $36 to $31.
- benzinga.com Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced an agreement with…
- benzinga.com B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $40 B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $40.
- benzinga.com Agios Pharma Says It Will Not Advance Tebapivat, Next-Gen Oral Pyruvate Kinase Activator, In Lower-Risk Myelodysplastic Syndromes As Phase 2b Trial Results Did Not Meet Predefined Threshold To Support Further Development In LR-MDS Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observedCAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) --…
- benzinga.com Agios Pharmaceuticals Announces EU Marketing Authorization For PYRUKYND In Adults For Treatment Of Anemia Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the European…
- benzinga.com Agios Pharmaceuticals Submits Supplemental New Drug Application To FDA Seeking Accelerated Approval Of Oral Pyruvate Kinase Activator Mitapivat; To Also Present New Data On Mitapivat At 31st European Hematology Association Congress Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the submission of…
- benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $36 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $36.
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com Agios Pharmaceuticals Q1 EPS $(1.69) Beats $(1.79) Estimate, Sales $20.746M Beat $13.646M Estimate Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(1.79) by 5.59 percent. This is a 9.03 percent decrease over losses of…
- benzinga.com B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $41 B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $44 to $41.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $50 HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $65 to $50.
benzinga.com US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.- benzinga.com JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $36 JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $36.
- benzinga.com Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $32 Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $28 to $32.
benzinga.com Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? .Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease.
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
benzinga.com Agios Pharmaceuticals Says It Will Pursue US Accelerated Approval For Mitapivat For Sickle Cell Disease Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will pursue…